Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly & Co. on Tuesday will ask the Seventh Circuit to set a standard process for determining when workers can pool ...
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.